Pomerantz LLP Initiates Class Action Lawsuit Against Spirit Aviation Holdings, Inc. – FLYYQ

NEW YORK CITY, NY / ACCESS Newswire / November 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in the securities of Spirit Aviation Holdings, Inc. ("Spirit" or the "Company") (OTCMKTS:FLYYQ).â?¯â?¯ The class action, filed in the United States District Court for the Southern District of […]

Bronstein, Gewirtz & Grossman, LLC Encourages Open Lending Corporation (LPRO) Stockholders to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / November 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Open Lending Corporation ("Open Lending" or "the Company") (NASDAQ:LPRO). Investors who purchased Open Lending securities prior to February 24, 2022, and continue to hold to the present, are encouraged

Class Action Litigation Filed by Pomerantz LLP Concerning Fly-E Group, Inc. – FLYE

NEW YORK, NY, NY / ACCESS Newswire / November 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fly-E Group, Inc. ("Fly-E" or the "Company") (NASDAQ:FLYE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are

Bronstein, Gewirtz & Grossman, LLC Is Investigating ModivCare, Inc. (MODV) And Encourages Investors to Connect

NEW YORK CITY, NY / ACCESS Newswire / November 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ModivCare, Inc. ("ModivCare" or "the Company") (NASDAQ:MODV). Investors who purchased ModivCare securities prior to November 3, 2022, and continue to hold to the present, are encouraged to obtain additional

Pomerantz LLP Commences Class Action Litigation Against Cytokinetics, Incorporate – CYTK

NEW YORK CITY, NY / ACCESS Newswire / November 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Cytokinetics, Incorporate ("Cytokinetics" or the "Company") (NASDAQ:CYTK).�� Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Coty, Inc. (COTY) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / November 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Coty, Inc. ("Coty" or "the Company") (NYSE:COTY). Investors who purchased Coty securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/COTY. Investigation

Pomerantz LLP Announces Securities Class Action Litigation Against Fluor Corporation – FLR

NEW YORK CITY, NY / ACCESS Newswire / November 2, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Fluor Corporation ("Fluor" or the "Company") (NYSE:FLR) and certain officers.�� The class action, filed in the United States District Court for the Northern District of Texas, Dallas Division, and docketed under

ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Fortinet, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FTNT

ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages Fortinet, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FTNT GlobeNewswire November 02, 2025 NEW YORK, Nov. 02, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Fortinet, Inc. (NASDAQ: FTNT) between November 8,

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Investors to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / November 2, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tvardi Therapeutics, Inc. ("Tvardi" or "the Company") (NASDAQ:TVRD). Investors who purchased Tvardi securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/TVRD.

Scroll to Top